ImmuPharma PLC (IMM)

London
2.30
-0.04(-1.71%)
  • Volume:
    62,869
  • Bid/Ask:
    2.30/2.47
  • Day's Range:
    2.30 - 2.30

IMM Overview

Prev. Close
2.34
Day's Range
2.3-2.3
Revenue
47K
Open
2.3
52 wk Range
2.1-9.5
EPS
-0.023
Volume
62,869
Market Cap
7.67M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,467,264
P/E Ratio
-0.989
Beta
1.39
1-Year Change
-56.91%
Shares Outstanding
333,403,115
Next Earnings Date
22 May 2023
What is your sentiment on ImmuPharma?
or
Vote to see community's results!

ImmuPharma PLC News

ImmuPharma PLC Company Profile

ImmuPharma PLC Company Profile

Employees
14

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Read More

Analyst Price Target

Average2.90 (+26.09% Upside)
High2.9
Low2.9
Price2.3
No. of Analysts1
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsBuyBuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell
  • The market doesnt seem think it will be positive for some reason. My guess is there will be a delay again. The FDA has been rather busy with monkeypox and new covid vaccines lately
    0
    • Tim McCarthy has sent another company into administration and lost shareholders millions and millions. My fear is history repeating itself. His track record is simply shocking. This is a 12 page document issued by the FDA, this is comprehendive and serious. IMM on it’s way to less than 1p
      0
    • Gary SmithI dont think its quite over yet. I bought back in as I feel a buyout could being discussed at the moment
      0
    • Ken Laing - You asked me a while beck where is tge 3.25p placing i touted. Gone even better then that and you can buy for circa 2.50p. IMM the charity that just keeps giving
      0
  • The conpany have restructured and turned things around. Much depends on FDA decidion on 29th August. If successful 15p if a duster 1p
    0
    • Hate to say i told you so but placing invound ar 3.25p. IMM CEO on £370k pa with no skin in the game. Ask yourself why?
      1
      • Wheres the 3p you promised? Lol
        0
      • Ken, and your prediction is? RNS today and SP is 6p to sell. The market don’t believe this inept BOD
        0
      • Ken Laing- Where’s your prediction now. IMM tge charity that jyst kerps giving. 2.54p to sell
        0
    • This is on the way to 4p. Lanstread still have a further £1m to offload, having sold at a losx and the crazy CLN £700k to be paid in December. Massive Red flag
      1
      • I bought some more today, thanks
        1
      • Are you trying to convince yourself here. You stated in September that you were buying at a crazily low price and hey ho lower it has gone lower. BOD only bought a tiny amount to placate angry shareholders. Lansteqd selling at a loss why? CLN’s £700k 10/12 and haemorraging money at an alarming rate. RED FLAG
        1
    • Added some more at this crazy price, its now my biggest holding in the portfolio.
      0
      • “The strengthened balance sheet position following the £6.5m placing in September 2020, provides a cash runway to end 2023. Lupus being an attractive market and poorly met medical need, Dr Malik believes the shares are oversold and reiterate their BUY rating and TP of 100p.”
        1
        • dr malik joking right? tp 100p give the company a market cap of 250M! tell me would u buy a company for 250m with 10m on the balance sheet?
          1
      • This report is worth readinghttps://thelifesciencesdivision.com/research/portal/?#/portal/the-life-sciences-division/research/c84d1aa9-f672-42fb-a774-ab7fe84a3a99/referrer/GB0033711010
        1
        • Looks like this has finally bottomed. I have built a substantial size position and expect to see it be 20p at least in a few months
          0
          • I had this at 9.16 unfortunately.
            0
            • its a time to load up ,in the stochastic over sold zone,just needs a bit of volume ,will move up very quickly
              0